10-K/A: Monopar Amends 2025 Annual Report, Boosts Liquidity

Monopar Therapeutics Inc. filed an amended annual report for 2025, correcting an audit report date and providing updated certifications, while revealing a strengthened financial position and ongoing pipeline development.

Summary

• The filing is an Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, primarily to correct a typographical error in the Audit Report date from March 27, 2025, to March 27, 2026, and to include currently dated certifications from the CEO and CFO.
• Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and novel radiopharmaceuticals (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) for oncology.
• The company reported an accumulated deficit of approximately $89.5 million as of December 31, 2025, and has not generated any revenue since inception.
• Net loss for the year ended December 31, 2025, was $(13,716,894), an improvement from $(15,586,419) in 2024.
• Research and development (R&D) expenses decreased to $9,904,225 in 2025 from $13,005,986 in 2024.
• General and administrative (G&A) expenses increased to $6,800,190 in 2025 from $3,155,735 in 2024.
• Cash and cash equivalents significantly increased to $61,833,552 as of December 31, 2025, from $45,816,289 in 2024.
• Investments also saw a substantial increase to $78,565,491 as of December 31, 2025, from $14,395,913 in 2024.
• Total assets grew to $140,717,709 as of December 31, 2025, from $60,291,071 in 2024.
• Total stockholders' equity increased to $137,827,553 as of December 31, 2025, from $55,036,771 in 2024.
• Net loss per share (basic and diluted) was $(1.85) in 2025, compared to $(4.11) in 2024.
• Weighted average shares outstanding (basic and diluted) increased to 7,411,121 in 2025 from 3,790,202 in 2024, reflecting capital raises.
• In September 2025, the company completed an underwritten public offering, raising approximately $126.9 million in net proceeds from common stock and pre-funded warrants.
• Concurrently, the company repurchased 550,229 shares of its common stock from Tactic Pharma LLC for $35 million.
• Management estimates that currently available cash will provide sufficient funds to meet obligations at least through December 31, 2027, and has no substantial doubt about its ability to continue as a going concern for that period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, primarily due to the strengthened financial position from the recent capital raise and reduced net loss, which extends the company's operational runway. However, the continued lack of revenue and reliance on future funding for pipeline development temper the overall sentiment.

Positives

• Net loss decreased from $(15,586,419) in 2024 to $(13,716,894) in 2025, indicating improved operational efficiency or reduced expenses.
• Cash and cash equivalents increased significantly to $61,833,552 as of December 31, 2025, from $45,816,289 in 2024, bolstering liquidity.
• Investments grew substantially to $78,565,491 in 2025 from $14,395,913 in 2024, reflecting strategic cash management.
• A successful underwritten public offering in September 2025 raised approximately $126.9 million in net proceeds, strengthening the company's financial position.
• Management projects sufficient funds to meet obligations through December 31, 2027, alleviating immediate going concern doubts.
• R&D expenses decreased by over $3 million in 2025 compared to 2024, potentially indicating more focused or efficient development activities.
• The company secured full ownership and title to its lead MNPR-101 radiopharmaceutical platform through an amended collaboration agreement with NorthStar Medical Radioisotopes, LLC.

Negatives

• The company continues to incur substantial operating losses, with an accumulated deficit of $89.5 million as of December 31, 2025.
• No revenue has been generated since inception, highlighting the pre-commercial stage of all product candidates.
• General and administrative expenses increased significantly from $3,155,735 in 2024 to $6,800,190 in 2025.
• The weighted average shares outstanding nearly doubled from 3,790,202 in 2024 to 7,411,121 in 2025, indicating significant shareholder dilution from capital raises.
• The company anticipates seeking additional capital to fund future operations, which may lead to further dilution.

Risks

• Many biopharmaceutical companies never become profitable and are acquired, merged, or liquidated before successfully developing any product that generates revenue.
• The company has incurred losses since inception and expects to continue to incur substantial operating losses over the next several years.
• The ability to raise sufficient funds to support continued clinical, regulatory, pre-commercial, and commercial development, and to make contractual future milestone payments, is uncertain.
• The amount of future losses, and when, if ever, the company would become profitable, are uncertain.
• The ability to generate revenue and achieve profitability depends on successfully completing product candidate development, obtaining regulatory approvals, establishing manufacturing/quality, sales, marketing, and distribution arrangements, obtaining adequate reimbursement, and raising sufficient funds.
• Internal Revenue Code Sections 382 and 383 may limit the use of net operating loss (NOL) carryforwards and R&D credits due to expected future equity raises.
• Cash and cash equivalents are maintained at financial institutions with balances in excess of FDIC insurable limits, posing a concentration of credit risk.
• The company cannot reliably predict when it will be able to commence a Phase 2 clinical trial for MNPR-101, which is a condition for a milestone payment under the XOMA Ltd. license agreement.

Future Outlook

Management estimates that currently available cash will provide sufficient funds to enable the company to meet its obligations at least through December 31, 2027. The company expects to continue to incur substantial operating losses over the next several years and anticipates seeking additional capital to fund future operations. The ability to generate revenue and achieve profitability is uncertain and depends on successful development of product candidates, obtaining necessary regulatory approvals, establishing manufacturing, sales, marketing, and distribution arrangements, obtaining adequate reimbursement, and raising sufficient funds. The company cannot reliably predict when a Phase 2 clinical trial for MNPR-101 will commence. The company is also assessing the potential implications of the 'One Big Beautiful Bill Act' (OBBBA) tax legislation on its operations and financial statements.

Management Comments

• Chandler D. Robinson, Chief Executive Officer, and Quan Vu, Chief Financial Officer, certified that the Annual Report on Form 10-K/A fully complies with SEC requirements and fairly presents the company's financial condition and results of operations.
• They are responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting, designed to ensure material information is known and to provide reasonable assurance regarding financial reporting reliability.
• They evaluated the effectiveness of disclosure controls and procedures and disclosed any material changes in internal control over financial reporting.
• They disclosed any significant deficiencies, material weaknesses, or fraud involving management or employees with significant roles in internal control over financial reporting to auditors and the audit committee.
• Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through December 31, 2027.
• Management has determined that, based upon the Company's current available cash and cash equivalents, there is no substantial doubt about its ability to continue as a going concern through December 31, 2027.

Industry Context

StockSavvy.ai notes that Monopar operates in the highly capital-intensive and risky biopharmaceutical sector, characterized by long development cycles and significant R&D investment. The company's dual focus on a late-stage Wilson disease candidate and novel radiopharmaceuticals for oncology positions it in competitive therapeutic areas. The reliance on licensing agreements (Alexion, XOMA) and strategic supply agreements (NorthStar) is a common strategy for smaller biotechs to expand their pipeline and secure critical resources without extensive in-house infrastructure. The continued net losses and explicit need for future capital raises are typical for clinical-stage companies prior to achieving commercialization and profitability.

Comparison to Industry Standards

• Monopar's accumulated deficit of $89.5 million and lack of revenue since inception are common for clinical-stage biopharmaceutical companies, which typically operate at a loss for many years while developing product candidates, similar to peers like smaller oncology or rare disease focused biotechs such as Oncternal Therapeutics or Acer Therapeutics at comparable development stages.
• The significant capital raise of approximately $126.9 million in September 2025 demonstrates access to capital markets, which is crucial in the biotech industry, comparable to other small-to-mid cap biotechs securing funding for pipeline advancement, such as Relay Therapeutics or Black Diamond Therapeutics in their early clinical phases.
• The licensing agreement for ALXN1840 (a late-stage asset) from Alexion Pharmaceuticals, a subsidiary of AstraZeneca, aligns with industry trends where larger pharmaceutical companies divest non-core assets to smaller, specialized firms for further development, a strategy seen with companies like BridgeBio Pharma acquiring assets from larger pharmaceutical partners.
• The development of radiopharmaceuticals like MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac places Monopar in a growing segment of oncology, with competitors like Novartis (Lutathera) and Bayer (Xofigo) having established products, and numerous other companies like Fusion Pharmaceuticals and RayzeBio in various stages of developing novel radio-ligand therapies.
• The 1-for-5 reverse stock split in August 2024 to regain Nasdaq compliance is a common measure taken by companies whose stock price has fallen below minimum listing requirements, seen across various industries, particularly in the small-cap biotech space, for example, similar actions taken by companies like Sorrento Therapeutics or Aeterna Zentaris in recent years.

Corporate Governance

Legal Proceedings

• No claims have been asserted to date regarding legal contingencies in the ordinary course of business.

Related Party Transactions

• On September 24, 2025, the company entered into a Share Purchase Agreement with Tactic Pharma LLC, an existing significant stockholder (beneficially owned 4.1% of common stock after the repurchase).
• The company repurchased 550,229 shares of its common stock from Tactic Pharma for $35 million at a purchase price of $63.6098 per share, which equaled the public offering price per share less underwriting discounts and commissions.
• Chandler D. Robinson, Monopar's Chief Executive Officer and a Board member, is a minority owner and non-controlling Managing Member of Tactic Pharma.

Stakeholder Impact

• **Shareholders:** Experienced significant dilution from the September 2025 public offering, increasing weighted average shares outstanding. The share repurchase from a related party could be viewed with scrutiny, though it was at market-related terms. The reverse stock split impacted the number of shares held and per-share price. Future value depends on successful pipeline development and avoiding further substantial dilution.
• **Employees:** Benefit from stock-based compensation plans (stock options and restricted stock units) as incentives, with new grants made in 2025.
• **Creditors/Suppliers:** The strengthened cash and investment position significantly improves the company's ability to meet its financial obligations and operational expenses through at least December 31, 2027.

Next Steps

• Continued clinical development of ALXN1840 for Wilson disease.
• Continued clinical development of radiopharmaceutical programs (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) for oncology.
• Seeking additional capital to fund future operations and pipeline advancement.
• Potential commencement of a Phase 2 clinical trial for MNPR-101, which would trigger a milestone payment to XOMA Ltd.
• Monitoring future administrative guidance and regulations regarding the 'One Big Beautiful Bill Act' (OBBBA) tax legislation.

Key Dates

Recommendation

Monopar Therapeutics has significantly bolstered its liquidity through a $126.9 million capital raise and reduced its net loss in 2025, extending its operational runway through December 2027. The company is advancing a late-stage Wilson disease candidate and multiple radiopharmaceutical oncology programs, which are positive developments. However, as a pre-revenue clinical-stage biopharmaceutical company, it faces substantial ongoing operating losses and will require significant additional capital to fund future development, regulatory approvals, and potential commercialization. The inherent risks of drug development, coupled with potential future dilution, warrant a 'hold' recommendation, advising investors to monitor pipeline progress and future financing strategies closely.

Keywords

Biopharmaceutical, Clinical-stage, Wilson disease, Radiopharmaceuticals, Oncology, ALXN1840, MNPR-101, SEC filing, 10-K/A, Financial report, Corporate governance, Capital raise, Share repurchase